Hôpital Franco-Britannique-Fondation Cognacq-Jay
Quick facts
Phase 3 pipeline
- Aflibercept-mFOLFIRI3 · Oncology
Aflibercept-mFOLFIRI3 is a combination regimen that pairs aflibercept (a VEGF trap) with modified FOLFIRI chemotherapy to inhibit angiogenesis while delivering cytotoxic chemotherapy.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Hôpital Franco-Britannique-Fondation Cognacq-Jay portfolio CI brief
- Hôpital Franco-Britannique-Fondation Cognacq-Jay pipeline updates RSS
Frequently asked questions about Hôpital Franco-Britannique-Fondation Cognacq-Jay
What is Hôpital Franco-Britannique-Fondation Cognacq-Jay's pipeline?
Hôpital Franco-Britannique-Fondation Cognacq-Jay has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Aflibercept-mFOLFIRI3.
Related
- Sector hub: All tracked pharma companies